Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive renal cyst formation and expansion. Several clinical trials show that somatostatin analogs halt cyst growth and progression of ADPKD by inhibiting adenosine 3 0 ,5 0 -cyclic monophosphate (cAMP) signaling. However, two studies suggest that the effect of the somatostatin analog octreotide on kidney growth during the first year of treatment is reduced in the subsequent follow-ups and the kidney enlargement resumes. We hypothesize that this biphasic change in kidney growth during octreotide treatment may be due to changes in somatostatin receptor 2 (SSTR2) expression. Here we analyzed the expression of renal SSTR2 in various polycystic kidney disease (PKD) mouse models in which PKD1 gene expression was disrupted on postnatal day 10 or 18 by tamoxifen. Using immunohistochemical analysis, we showed that the distribution of SSTR2 in murine kidneys is mainly in distal tubules and collecting ducts. In addition, in both PKD models, we observed a significant decrease in SSTR2 expression in epithelia of dilated tubules and cystic epithelia in mice with end stage of PKD compared to wild-type mice. These findings were further confirmed by quantitative PCR (qPCR) on mRNA levels of SSTR2. In conclusion, our data show that SSTR2 expression levels are reduced during kidney cyst growth, which may suggest reduced efficacy in long-term treatment with somatostatin analogs.
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent hereditary disorder caused by a mutation in the PKD1 or PKD2 gene. 1, 2 The disease is characterized by progressive development of numerous fluid-filled kidney cysts accompanied by the formation of interstitial fibrosis, leading to destruction of kidney architecture, and ultimately kidney failure. [1] [2] [3] Extra-renal complications can occur during ADPKD, such as cysts in the liver and pancreas, hypertension, and cerebral aneurysms. 3 Although tolvaptan has recently become available for selected ADPKD patients to slow the progression of ADPKD, there is currently no cure. [4] [5] [6] In order to meet the urgent needs of patients, considerable effort has been made to explore the mechanisms that are essential for the development of ADPKD, allowing identification of several potential targets for therapeutic interventions. 7 Renal cyst formation and expansion during ADPKD are the results of excessive epithelial cell proliferation, continuous luminal fluid secretion as well as extracellular matrix remodeling. 4, 8 Previous studies implicate that one of the mechanisms associated with these processes is enhanced
Impact statement
Somatostatin (SST) analogs have been shown to halt cyst growth and progression of autosomal dominant polycystic kidney disease by several clinical trials. However, two studies suggest that the effect of the SST analog octreotide on kidney growth during the first year of treatment is reduced in the subsequent follow-ups and the kidney enlargement resumes. This biphasic change in kidney growth during octreotide treatment may be partially explained by alterations in SSTR2 expression. Here, we found that SSTR2 is mainly expressed in distal tubules and collecting ducts in murine kidneys, and the expression of SSTR2 decreases during cyst growth in two PKD mouse models. Our data may thus provide possible explanations for the lack of efficacy in long-term treatment with SST analogs. intracellular cAMP signaling. 5, 9, 10 Therefore, the molecules that mediate cAMP signaling may be potential therapeutic targets for treating ADPKD. Indeed, activation of the vasopressin-2 receptor (V2R) induces the generation of cAMP, while targeting V2R with its antagonist tolvaptan reduces cAMP levels in kidney epithelial cells and limits cystogenesis in several PKD models. [11] [12] [13] [14] Furthermore, several completed or currently active clinical studies under the TEMPO program indicate that tolvaptan shows a treatment effect in reducing total kidney volume. 6, 15, 16 In addition, somatostatin (SST), a cyclic 14 amino acid peptide hormone, exerts inhibitory effects on cAMP signaling through binding to its G-protein-coupled receptors (SSTR1-5). 17 SST has been proven to inhibit vasopressin-induced cAMP formation in Madin-Darby Canine Kidney (MDCK) cells and diminishes cAMP concentrations in rat cortical and medullary collecting tubules. 18, 19 Targeting SSTRs with SST analogs inhibits cell proliferation, cAMP levels and hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease. 11, [20] [21] [22] In consistence with these observations, a few completed clinical trials with the primary focus of inhibiting cAMP using SST analogs (octreotide or lanreotide) have indicated potential clinical benefit in patients with ADPKD. [23] [24] [25] [26] [27] The administration of octreotide for periods of 6-12 months effectively inhibits the increase in total kidney volume. 25, 26 This has been confirmed in a six-month clinical trial which demonstrated that lanreotide decreases total kidney volume in 43 ADPKD patients. 27 Interestingly, two relative small studies suggest that the efficacy of SST analog treatment appears to reduce with longer follow-ups. 23, 24 Long-acting octreotide halts kidney growth during the first year of treatment, but with ongoing treatment, tolerance develops and the effect is reduced during year 2. In the future, more information on efficacy and tolerance of prolonged somatostatin treatment will come from an ongoing clinical trial with a period of 120 weeks. 28 Because of this biphasic change in kidney growth during SST analogs treatment, we propose that SSTRs might be progressively downregulated with ADPKD development, leading curtailed long-term efficacy. Since both octreotide and lanreotide have the highest affinity for SSTR2, 29 we examined expression of this receptor in various PKD mouse models at different time points after disruption of the PKD1 gene.
Materials and methods
Cell culture SV40 large T-antigen immortalized murine wild type (WT) proximal tubular epithelial cells (PTEC) were derived from a Pkd1 lox,lox mouse and cultured as previously described. 30 Briefly, PTEC cells were maintained at 37 C and 5% CO 2 in DMEM/F12 with GlutaMAX (Gibco, Fisher Scientific) supplemented with 100 U/mL penicillin/streptomycin (Gibco, Waltham, MA), 2% Ultroser G (Pall BioSepra, France), 1Â insulin-transferrin-selenium-ethanolamine, 25 ng/L prostaglandin E1 (Sigma-Aldrich, Netherlands), and 30 ng/L hydrocortisone (Sigma-Aldrich, Netherlands). Murine collecting duct mIMCD-3 cells (American Type Culture Collection, ATCC, UK) were maintained in DMEM/F12 with GlutaMAX (Gibco) supplemented with 10% fetal calf serum and 100 U/mL penicillin/streptomycin (Gibco).
Animal models of polycystic kidney disease
The tamoxifen-inducible kidney-specific Pkd1-deletion (tam-KspCad-CreERT2;Pkd1 lox2-11;lox2-11 or in short iKspPkd1 del ) mice and oral tamoxifen administration have been described previously. 31, 32 The mice received 150 mg/kg tamoxifen at postnatal day PN18-PN19 (PN18 model) or 15 mg/kg tamoxifen at PN10-PN11 (PN10 model). PN18 mice were sacrificed at 4 or 12 (n ¼ 6) weeks after tamoxifen administration and PN10 mice were sacrificed at 1 or 3 weeks (n ¼ 5) after tamoxifen administration. Mice were bred at the animal care facility of the Leiden University Medical Center (LUMC). 0 . Data were analyzed with LightCycler 480 Software, version 1.5 (Roche). Gene expression was calculated using the LinRegPCR method as described previously 33 and normalized to HPRT expression, giving the relative gene expression. Mean gene expressions and standard deviations of the different groups were calculated.
(Immuno)histochemistry
Kidney tissues were fixed in formalin, embedded in paraffin, and 4-lm-thick slides were subsequently stained with hematoxylin and eosin according to routine procedures. Segment marker staining was performed with sequential renal sections (4 mm), using rabbit polyclonal anti-megalin (Pathology LUMC), goat polyclonal anti-Tamm-Horsfall protein (uromodulin; Organon Teknika-Cappel), and rabbit polyclonal anti-aquaporin-2 (Calbiochem, Germany) as previously described. 34 SSTR2 staining was performed with a rabbit monoclonal anti-SSTR2 antibody (Abcam, ab134152). A horseradish peroxidase (HRP)-conjugated polymer detection system was applied for visualization using rabbit envision HRP (Agilent Dako, Amstelveen) or rabbit anti-goat HRP (Dako) as the secondary antibody. Immune reactions were revealed using diaminobenzidine and counterstained with hematoxylin.
cAMP assay
Levels of cAMP were measured in mice control and PN10 cystic kidneys (n ¼ 2 for each experimental condition). cAMP levels were determined by the cAMP enzyme immunoassay kit (Sigma-Aldrich Chemie N.V.).
Statistical analysis
Statistical comparisons between groups were performed using an unpaired t-test. p values less than 0.05 were considered significant.
Results
The expression pattern of SSTR2 in normal mouse kidneys
We investigated the expression pattern of SSTR2 in paraffin-embedded kidney sections of adult WT mice. Proximal tubules, distal tubules, and collecting ducts were identified by staining for their specific markers megalin, Tamm-Horsfall protein, and aquaporin-2, respectively (Figure 1(a) ). SSTR2 was mainly detected in a large proportion of distal tubules and collecting ducts. In contrast, SSTR2 staining was almost absent in proximal tubules. To verify this observation, we subsequently examined the mRNA levels of SSTR2 and SSTR5 in PTEC and mIMCD-3 cells that derived from proximal tubules and collecting ducts, respectively (Figure 1(b) ). The mRNA level of SSTR2 was higher in the collecting ducts than in the proximal tubules, confirming the results of the SSTR2 immunostaining.
SSTR2 expression decreased during cyst growth in two PKD mouse models
We next examined the SSTR2 expression in the Pkd1 del models during different phases of disease. Deletion of the Pkd1 gene in mice of different age results in distinct PKD phenotypes. 35, 36 Previous studies have indicated that inactivation of Pkd1 at prenatal day 10 results in rapid cyst formation within three weeks, and cysts are primarily from distal tubules and collecting ducts. 36 In contrast, the PN18 model has a much slower progression of PKD and develops polycystic kidneys within three months, with cysts derived from all tubular segments 36 ( Figure 2 ). At the early stage of PKD in the PN18 model (PN18 þ 4weeks), SSTR2 expression was still observed in most of the dilated tubules originating from distal tubules and collecting ducts. At 12 weeks after tamoxifen administration, PN18 mice developed massive cystic kidneys and showed a clear loss of SSTR2 expression in almost all cysts compared with PN18 mice at four weeks (Figure 3(a) and also compare Figure 3 (a) and (b) to Figure 1(a) ). Similarly, PN10 model also showed reduction in SSTR2 levels along ........................................................................................................................................................ .... ............................................................................................................................................................ the disease progression compared with WT mice. SSTR2 expression was decreased in cystic epithelia at mild stage (PN10 þ 1weeks) of PKD and was lost in the majority of cysts at the end stage of the disease (compare Figure 3(c) to Figure 1(a) ). To verify this finding, we also analyzed the mRNA levels of SSTR2 in the animal kidney lysates, using SSTR5 as a comparison. The mRNA levels of SSTR2 from PN18 þ 12 weeks mice were significantly lower compared to WT mice, whereas this reduction was not detected in PN10 mice (Figure 3(d) and (e) ).
Discussion
ADPKD is a heterogenetic disorder caused by mutations in the PKD1 or PKD2 gene, but additional factors are also involved. 1, 2, 8, 36 There is compelling evidence that aberrant cAMP signaling plays a critical role in renal and liver cystogenesis. 5 Several animal models for cystic kidney disease (including ours) demonstrate elevated cAMP content in kidneys ( Figure S1 ) and show that reduced cAMP increase, by targeting SSTRs, limits disease progression. 5, 11, [20] [21] [22] Based on these findings and the fact that SSTRs are expressed in human kidneys, 37 SST analogs have been tested in several clinical trials for treating ADPKD. Although somatostatin analogs significantly halt cyst growth and progression of ADPKD during the first year of treatment, the effect then reduces, as observed for octreotide. [23] [24] [25] [26] [27] [28] The reduced long-term treatment effect of SST analogs may be partially explained by the data described in this study. Here, we show that renal SSTR2 expression is downregulated during cyst growth in mice with ADPKD. In two PKD mouse models, expression of SSTR2 declined progressively in dilated distal tubules and collecting ducts and was completely lost in almost all cystic epithelia at the end stage of the disease. The findings in immunohistochemistry were supported by data on corresponding mRNA expression of SSTR2 in PN18 mice, but not in PN10 mice. This may be due to the fact that PN10 mice were still in developmental stage and the proliferation indices varied between animals, so that the mRNA expression could not correctly reflect protein expression.
We also studied the SSTR2 expression in human material in order to correlate our findings with human disease. In immunohistochemical analysis, we observed that SSTR2 is mildly expressed in all kidney segments, while high expression was mainly observed in proximal tubules. Importantly, cystic lesions of ADPKD patients also showed decreased expression of SSTR2 in epithelia of dilated tubules and cystic epithelia compared with healthy controls (Figure S2(a) ). Using antibodies generated against the same immunizing peptide ETQRTLLNGDLQTSI, corresponding to residues 335-369 of human SSTR2, other investigators detected renal SSTR2 expression in the same pattern as we observed in immunohistochemical experiments. [38] [39] [40] [41] However, the results from immunohistochemical analysis are not in line with our qPCR analysis, which showed more SSTR2 expression in cells derived from human collecting ducts than proximal tubules, similar as observed in mice ( Figure S2(b) ).
Therefore, we are not fully confident with the immunohistochemistry results from the human tissue. Further research to confirm SSTR2 expression pattern in human kidney using another experimental method is required.
Our findings, showing decreased SSTR2 expression in kidney cysts, are in line with the previous study reporting diminished expression of SSTR1 and SSTR2 in cystic cholangiocytes of animal models and PKD patients. 21 The mechanism by which SSTR2 expression is downregulated during cyst growth remains elusive. However, it has been shown that treatment with SST analogs, octreotide, and pasireotide, increases immunoreactivity of SSTR2 in cystic cholangiocytes. 21 Furthermore, it has been suggested that SST has the ability to upregulate SSTR2 at cell membrane. 42 Thus, it is tempting to speculate that the decrease in SSTR2 expression may be due to defective epithelial differentiation, which could be partially restored by SST analogs treatment during the progression of cystic kidney disease.
Several issues should be taken into consideration when interpreting our data. First, although our Pkd1 del models are well-established models to study ADPKD, they do not completely mimic the progression of cystic disease in patients with ADPKD. For example, the Pkd1 del model has relatively synchronized cyst formation, since deletions in the Pkd1 gene can happen at the same time in much larger numbers of cells than in human ADPKD. 8 Therefore, our descriptive data obtained in animal models cannot fully represent the human situation. Second, although octreotide, lanreotide and pasireotide mainly target SSTR2, SSTR5 also shows relatively high affinity for SST analogs 29 and its expression should be investigated in normal and cystic kidneys. However, the commercially available antibody that is frequently used to detect SSTR5 in murine tissue failed to produce consistent and reproducible data 43 (data not shown), which may be explained by the fact that it is only rat specific. Finally, our data suggested that the SSTR2 expression pattern may be different between human and murine kidneys, which should be kept in mind when targeting SSTR2 with SST analogs.
In conclusion, we present the distribution of SSTR2 in murine kidneys, and irrespective of the potential clinical relevance, our data suggest that the expression of SSTR2 decreases during the development of ADPKD. Reduced target expression may also be taken into account when targeting other trans-membrane receptors for treating ADPKD.
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